Skip to main content

Lexicon Pharmaceuticals Value Stock - Dividend - Research Selection

Lexicon pharmaceuticals

ISIN: US5288723027 , WKN: A14SSK

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 clinical development for the treatment of diabetes; and LX9211 that is in Phase 1 clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential

2025-05-21
We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) was one of the stocks that was covered in that article. Wall Street analysts believe LXRX has a 285% upside potential over the next 12 months. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is a biopharmaceutical company with a pioneering approach […]

SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology

2025-05-19
Lexicon is evaluating the safety and efficacy of sotagliflozin in patients with both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) Pivotal Phase 3 clinical trial is actively enrolling patients in 20 countries, with all sites expected to be operational by Q3 2025 THE WOODLANDS, Texas, May 19, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced details of its “SOtaglifloziN in Patients with SymptomATic obstructive And non-obstructive Hypertroph

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

2025-05-17
As you might know, Lexicon Pharmaceuticals, Inc. ( NASDAQ:LXRX ) just kicked off its latest first-quarter results with...

Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna

2025-05-14
Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ...

2025-05-14
Lexicon Pharmaceuticals Inc (LXRX) secures a lucrative deal with Novo Nordisk and advances its clinical pipeline, while navigating financial hurdles and competitive pressures.

Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2025 Earnings Call Transcript

2025-05-13
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2025 Earnings Conference Call May 13, 2025 5:00 PM ETCompany ParticipantsLisa DeFrancesco - Senior Vice...

Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates

2025-05-13
Lexicon (LXRX) delivered earnings and revenue surprises of 30% and 23.52%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Lexicon: Q1 Earnings Snapshot

2025-05-13
THE WOODLANDS, Texas (AP) — Lexicon Pharmaceuticals Inc. LXRX) on Tuesday reported a loss of $25.3 million in its first quarter. On a per-share basis, the The Woodlands, Texas-based company said it had a loss of 7 cents.

Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates

2025-05-13
Company had a strong start to 2025, emerging as an R&D-focused organization Exclusive license agreement with Novo Nordisk for LX9851 executed; IND-enabling studies on track for completion in 2025 Phase 2b PROGRESS study confirmed 10 mg pilavapadin as appropriate dose for advancement into Phase 3 development for diabetic peripheral neuropathic pain Conference call and webcast at 5:00 pm ET THE WOODLANDS, Texas, May 13, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today r

Lexicon Pharmaceuticals, Inc. 2025 Q1 - Results - Earnings Call Presentation

2025-05-13
The following slide deck was published by Lexicon Pharmaceuticals, Inc.